Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease
NCT05901818Phase 1Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous induced neural stem cell-derived DA precursor cells in Parkinson's disease (PD), sponsored by Xuanwu Hospital. Primary endpoints: Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, Part III at 12 months and Incidence and severity of transplant-related adverse events at 12 months. Started Apr 2021; status: recruiting.
02
Drugs
autologous induced neural stem cell-derived DA precursor cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05901818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901818.